[Dronedarone: the new antiarrythmic agent?].
Dronedarone is recommended as the successor drug to amiodarone because a faster onset of effects and less side effects are to be expected. This review describes the pharmacological properties of this multi-channel blocker and summarizes the results from recent studies proving successful antiarrhythmic therapy using dronedarone in patients with atrial fibrillation.
Brachmann
J
J
II. Medizinische Klinik, Klinikum Coburg, Ketschendorfer Strasse 33, Coburg, Germany. johannes.brachmann@klinikum-coburg.de
Sinha
A-M
AM
D000638:Amiodarone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage*; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000503:physiopathology*; D000077764:Dronedarone; D006329:Heart Conduction System / Q000187:drug effects / Q000503:physiopathology*; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D008955:Models, Cardiovascular
D000889:Anti-Arrhythmia Agents; D000077764:Dronedarone; D000638:Amiodarone